Precision medicine approaches for treating hepatocellular carcinoma

Nadia Ahmed, Kevin Benny, Sohail Siraj, Hufsa Ali, Riyaz Basha

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Hepatocellular carcinoma (HCC) accounts for the majority of liver cancer diagnoses and deaths. Risk factors for HCC include viral infections, such as hepatitis B and C, heavy alcohol use, lifestyle choices, and certain inherited genetic disorders. The complex interheterogeneity and intraheterogeneity of HCC tumors requires a more individualized treatment approach. Precision medicine uses next-generation sequencing (NGS) to map a tumor’s genome to identify molecular alterations that are targetable by small molecules and immunotherapies. Although the most common oncogenic drivers of HCC are currently nonactionable, precision medicine technology has been utilized to identify biomarkers capable of predicting treatment response or primary resistance to guide clinical decision-making. This chapter will discuss the current advancements and challenges of precision medicine in HCC.

Original languageEnglish
Title of host publicationTheranostics and Precision Medicine for the Management of Hepatocellular Carcinoma
Subtitle of host publicationVolume 3: Translational and Clinical Outcomes
Number of pages13
ISBN (Electronic)9780323992831
ISBN (Print)9780323992848
StatePublished - 1 Jan 2022


  • biomarkers
  • Hepatocellular carcinoma
  • precision medicine
  • therapeutic outcomes


Dive into the research topics of 'Precision medicine approaches for treating hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this